文献类型：专利

英文题名：New pteridine compounds useful in preparing medicine for treating or preventing e.g. epidermal growth factor receptor, B-cell lymphocyte kinase, FLT3, human epidermal growth factor receptor, cancer or autoimmune diseases

作者：LI H;XU Y;ZHAO Z;LIU X;ZHOU W;BAI F;XUE M;ZHANG L;ZHANG Y

机构：[1]UNIV EAST CHINA SCI & TECHNOLOGY

申请号：CN106008511-A

申请日：2013-04-02

公开日：2016-10-12

语种：英文

收录：DERWENT

摘要：NOVELTY - Pteridine compounds (I) are new. USE - (I) are useful in preparing medicine for treating or preventing and inhibition of epidermal growth factor receptor, B-cell lymphocyte kinase, FLT3, human epidermal growth factor receptor, HER4, FLT1, CDk2, JAk2, LCk, LynA, ckit, PIM1, fibroblast growth factor receptor 3, fibroblast growth factor receptor 1, platelet derived growth factor receptor alpha , platelet derived growth factor receptor beta , kDR, SRC, ABL, Aurora B kinase, C-MET, BRAF, PKACa, IkkB, IGF1R, glycogen synthase kinase-3 beta , P38a and ERk1-mediated disease (including cancer or autoimmune diseases), where cancer including non-small cell lung cancer, breast cancer, prostate cancer, glioma, ovarian cancer, head and neck squamous cell carcinoma, cervical cancer, esophageal cancer, liver cancer, kidney cancer, pancreatic cancer, colon cancer, skin cancer, leukemia, lymphoma, stomach cancer, solid tumor, diffuse B cell lymphoma, chronic lymphocytic lymphoma, chronic lymphocytic leukemia, follicular lymphoma, B cell lymphoblastic leukemia, lymphoplasmacytic lymphoma, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, lymph node marginal zone B-cell lymphoma, coat cell lymphoma, Large B-cell lymphoma, intravascular large B-cell lymphoma, primary exudative lymphoma, Burkitt lymphoma, lymphomatoid granulomatousgia, lymphoblastic lymphoma, T-cell lymphoblastic Leukemia, T-cell granular lymphocytic leukemia, aggressive NK-cell leukemia, cutaneous T-cell lymphoma, reshaped large cell lymphoma, peripheral T-cell lymphoma, adult T-cell lymphoma, acute myeloid leukemia, acute lymphoblastic leukemia , acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic neutrophilic leukemia, acute undifferentiated leukemia, degenerative developmental large cell lymphoma, juvenile lymphocytic leukemia, juvenile granulocytic leukemia, adult T-cell ALL, acute myeloid leukemia with triple-spectrum myelodysplasia, mixed lineage leukemia, myelodysplastic syndrome, myelodysplastic syndrome, myeloproliferative disorders, multiple myeloma, and immunological disease including arthritis, lupus, inflammatory bowel disease, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, Still's disease, adolescent arthritis, diabetes, myasthenia gravis, Hashimoto's thyroiditis, Ord's thyroiditis, graves disease, Rheumatoid arthritis syndrome, Multiple sclerosis, Infectious neuritis, Acute disseminated encephalomyelitis, Addison disease, aplastic anemia, autoimmune hepatitis, optic neuritis, silver leukemia, graft versus host disease, transplant, transfusion allergic reactions, allergy, type I hypersensitivity, allergic conjunctivitis, allergic rhinitis or atopic dermatitis (all claimed). DETAILED DESCRIPTION - Pteridine compounds of formula (I) are new. n = 0 or 1; A and B = benzene ring with a variety of substituents or 5- or 6-membered heterocyclic ring; C1 = 7,8-dihydropteridine-2,8-diyl compound of formula (II), 2,8-dichloro-7,8-dihydropyrido(2,3-d)pyrimidine compound of formula (III) 1,2-dihydropyrimido(4,5-d)pyrimidine-1,7-diyl compound of formula (IV), 8,9-dihydro-7H-purine-2,9-diyl compound of formula (V), 8,9-dihydro-7H-purine-2,9-diyl compound of formula (VI), 8,9-dihydro-7H-purine-2,9-diyl compound of formula (VII), 7,8-dihydropteridine-2,8-diyl compound of formula (VIII), 7,8-dihydropyrido(2,3-d)pyrimidine-2,8-diyl compound of formula (IX), 1,2-dihydropyrimido(4,5-d)pyrimidine-1,7-diyl compound of formula (X), 8,9-dihydro-7H-purine-2,9-diyl compound of formula (XI), 1H-pyrazolo(3,4-d)pyrimidine-1,6-diyl compound of formula (XII), 2,3-dihydro-1H-pyrazolo(3,4-d)pyrimidine-1,6-diyl compound of formula (XIII), 5,8-dihydropteridine-2,8-diyl compound of formula (XIV), 5,8-dihydropyrido(2,3-d)pyrimidine-2,8-diyl compound of formula (XV), 1,4-dihydropyrimido(4,5-d)pyrimidine -1,7-diyl compound of formula (XVI), 6,7-dihydro-5H-pyrrolo(2,3-d)pyrimidine-2,7-diyl compound of formula (XVI), 7H-pyrrolo(2,3-d)pyrimidine-2,7-diyl compound of formula (XVIII), 6,7-dihydro-5H-pyrrolo(2,3-d)pyrimidine-2,7-dichloro compound of formula (XIX), 5,6,7,8-tetrahydropteridine-2,8-dichloro compound of formula (XX), 5,6,7,8-tetrahydropyrido(2,3-d)pyrimidine-2,8-dichloro compound of formula (XXI), 1,2,3,4-tetrahydropyrimido(4,5-d)pyrimidine-1,7-diyl compound of formula (XXII), 2,3-dihydro-1H-(1,2,3)triazolo(4,5-d)pyrimidine-3,5-diyl compound of formula (XXIII), 2,3-dihydro-1H-(1,2,3)triazolo(4,5-d)pyrimidine-3,5-diyl compound of formula (XXIV), 2,3-dihydro-1H-pyrazolo(3,4-d)pyrimidine-1,6-diyl compound of formula (XXV), 1,4-dihydropyrimido(5,4-e)(1,2,4)triazine-1,7-diyl compound of formula (XXVI), 1,2-dihydropyrimido(5,4-e)(1,2,4)triazine-1,7-diyl compound of formula (XXVII), 1,4-dihydropyrimido(4,5-e)(1,2,4)triazine-4,6-diyl compound of formula (XXVIII), 5,6,7,8-tetrahydropyrido(2,3-d)pyrimidine-2,8-diyl compound of formula (XXIX), 8,9-dihydro-7H-purine-2,9-diyl compound of formula (XXX), or 6,7-dihydro-5H-pyrrolo(2,3-d)pyrimidine-2,7-diyl compound of formula (XXXI); X = O, S and Se; R1 = H, halo, 1-6C alkoxy, optionally substituted 1-6C alkyl, optionally substituted aryl or optionally substituted aralkyl group; R2 = H, halo, 1-6C alkoxy, hydroxy, optionally substituted acyloxy group, amino group, optionally substituted amido group, optionally substituted 1-6C alkyl, cyano group, sulfonyl group, aminosulfonyl, carbamoyl, carboxy, optionally substituted alkoxycarbonyl group, optionally substituted phenyl, optionally substituted N-alkylpiperazinyl, optionally substituted morpholinyl, optionally substituted piperidinyl, optionally substituted pyrrolyl, optionally substituted pyrrolidinyl, -NRaRb or optionally substituted pyridyl; R3 = H, halo, 1-6C alkoxy, hydroxy, optionally substituted acyloxy, amino group, optionally substituted amido group, optionally substituted 1-6C alkyl, cyano group, sulfonyl group, aminosulfonyl group, carbamoyl group, carboxy group, optionally substituted alkoxycarbonyl, optionally substituted phenyl, optionally substituted N-alkylpiperazinyl, optionally substituted morpholinyl, optionally substituted piperidinyl, optionally substituted pyrrolyl, optionally substituted pyrrolidinyl, -NRaRb or optionally substituted pyridyl; Ra and Rb = alkyl and alkenyl; R3 = X1 = halo; and m and n = 0, 1, 2, 3 or 4.